Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: A software providing apparatus that provides software for performing data processing concerning an oncogene, the software operating on a virtual machine and including a software module that executes data processing concerning an oncogene and setting information for determining an operation at a time when the software module executes the data processing, the software providing apparatus comprising a receiving unit that receives an instruction concerning providing the software to an at least one predetermined user group; and a generating unit that, when the instruction has been received, instructs an information processing apparatus which stores a template of a virtual machine including the software to duplicate the template of the virtual machine, hereby causing the information processing apparatus to generate a new virtual machine including software to be provided to the at least one predetermined user group.

Abstract: There is provided a data generation apparatus including a display control unit that displays, on a screen, an image and borders of a plurality of partial images generated by dividing the image into a plurality of pieces while the image and the borders are superimposed together, an input unit that receives input of a label to be given to each of the plurality of partial images, and a generation unit that generates learning data for causing a learning model to learn by associating each of the plurality of partial images with the label given to the corresponding partial image of the plurality of partial images.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: A method for predicting ADCC activity in a subject, the method comprising the steps of: (a) preparing a biological sample from the subject, said sample including a leukocyte, (b) bringing a portion of the biological sample and an antibody into contact with each other, (c) detecting expression of at least one marker of ADCC activity selected from the group consisting of tumor necrosis factor super family 15, chemokine CXCL3, and interleukin 6 in the leukocyte in (i) the portion of the sample brought into contact with the antibody and in (ii) another portion of the sample not brought into contact with the antibody, (d) comparing an expression level in portion (i) with the expression level in portion (ii); and (e) predicting presence of the cytotoxic activity when the expression level in portion (i) is higher than the expression level in portion (ii)

Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

Abstract: Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1; DNAs encoding the antigenic polypeptides, or DNAs complementary thereto; a method for production of an anti-Chlamydia pneumoniae antibody, wherein the antigenic polypeptide is used as an antigen; a method for detection and/or measurement of an anti-Chlamydia pneumoniae antibody, which comprise the antigenic polypeptide as an antigen; agents for diagnosis of Chlamydia pneumoniae infections, which comprise the antigenic polypeptide as an active ingredient; fused proteins of an antigenic polypeptide of Chlamydia pneumoniae with dihydrofolate reudctase; a method for production of an anti-Chlamydia pneumoniae antibody, wherein the fused protein is used as an antigen; reagents for detection and/or measurement of an anti-Chlamydia pneumoniae antibody, which comprise the fused protein as an antigen; agents for diagnosis of Chlamydia pneumoniae infect

Abstract: Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1, DNAs encoding the antigenic polypeptides, or DNAs complementary thereto; a method for detection and/or measurement of an anti-Chlamydia pneumoniae antibody, wherein the antigenic polypeptide is used as an antigen; reagents for detection and/or measurement of an anti-Chlamydia pneumoniae antibody, which comprise the antigenic polypeptide as an antigen; agents for diagnosis of Chlamydia pneumoniae infections, which comprise the antigenic polypeptide as an active ingredient; fused proteins of an antigenic polypeptide of Chlamydia pneumoniae with dihydrotolate reductase, in which polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1 is bound to the polypeptide of SEQ ID NO: 14 either directly or via an intervening amino acid or amino acid sequence; DNAs encoding the fused proteins, or DNAs co

Abstract: Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1; DNAs encoding the antigenic polypeptides, or DNAs complementary thereto; DNAs encoding the probes and primers for detection and/or measurement of Chlamydia pneumoniae gene. The present invention further provides a method for detection and/or measurement of Chlamydia pneumoniae gene, wherein the probe or primer is used; reagents for detection and/or measurement of Chlamydia pneumoniae gene, which comprise the probe or primer; and agents for diagnosis of Chlamydia pneumoniae infections, which comprise the probe or primer as an active ingredient.

Abstract: Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1; DNAs encoding said antigenic polypeptides, or DNAs complementary thereto; recombinant vectors carrying said DNAs; transformants containing said recombinant vectors; a method for production of an anti-Chlamydia pneumoniae antibody, wherein the antigenic polypeptide is used as an antigen; fused proteins of an antigenic polypeptide of Chlamydia pneumoniae with dihydrofolate reductase, in which polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1 is bound to the polypeptide of SEQ ID NO: 14 either directly or via an intervening amino acid or amino acid sequence; DNAs encoding the fused proteins, or DNAs complementary thereto; recombinant vectors carrying the DNAs; transformants containing said recombinant vectors; a method for production of an anti-Chlamydia pneumoniae antibody; probes and p

Abstract: The present invention relates to a Chlamydia pneumoniae antigen comprising protein derived from the outer membrane of Chlamydia pneumoniae, a method for producing a Chlamydia pneumoniae antigen which comprises solubilizing the cytosol and the cytoplasmic membrane of Chlamydia pneumoniae elementary body with an ionic detergent, and then removing the solubilized portion to obtain the residue, a method for measuring an anti-Chlamydia pneumoniae antibody which comprises using the Chlamydia pneumoniae antigen, and a reagent for measuring anti-Chlamydia pneumoniae antibody, said reagent comprising the Chlamydia pneumoniae antigen.In accordance with the present invention, there are provided a Chlamydia pneumoniae antigen which has a high species-specificity, very few clinically problematic false negatives, and few false positives, a method for producing said antigen, a method for measuring an anti-Chlamydia pneumoniae antibody, and a reagent for measuring an anti-Chlamydia pneumoniae antibody.